LY3540378

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyHeart FailureHeart Failure With Preserved Ejection Fraction

Phase 1

A Study of LY3540378 in Healthy Participants

CompletedNCT04768855

Eli Lilly and CompanyHealthy

Start: 2021-03-17End: 2022-05-30Updated: 2022-06-21

Phase 2

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

TerminatedNCT05592275

Eli Lilly and CompanyHeart Failure, Heart Failure With Preserved Ejection Fraction

Start: 2023-02-03End: 2025-01-22Updated: 2026-02-05

Related Papers

Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial.

2025-08-311 citations

Long-acting relaxin analogues: a novel tool in cardiology.

2025-08-04

Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial

Nephrology Dialysis Transplantation2024-05-237 citations